

The 10th Annual Meeting of AOCC (AOCC2022)

Program at Glance

	June 17 (Fri)			June 18 (Sat)		
	Track 1	Track 2	Track 3	Track 1	Track 2	Track 3
8:00						
	Morning Seminar 1 OLYMPUS MARKETING, INC.	Morning Seminar 2 EA Pharma Co., Ltd. / SEKISUI MEDICAL CO., LTD.		Morning Seminar 3 DAIICHI SANKYO COMPANY, LIMITED	Morning Seminar 4 KYORIN Pharmaceutical Co., Ltd	
9:00	Opening Ceremony					
	Session 1 <u>Asian Clinical Highlights</u>	Distinguished 1 PRO research <u>Patient cohort study in IBD</u>	Oral Session 1	Distinguished 4 Endoscopic surgery <u>Endoscopic advances in IBD - radial incision cutting -</u>	Distinguished 5 Future therapeutics <u>Futures of IBD management</u>	Session 6 Pediatric IBD2 Biologics <u>Applying Biologics for pediatric IBD in Asia: For the better outcome</u>
10:00						
	Distinguished 2 Stem cell and cancer <u>Recent advances in stem cell and cancer biology in IBD</u>	Session 2 Genetics <u>Advances in IBD genetics</u>	Oral Session 2	Session 7 <u>Management of IBD in special situations</u>	Session 8 FMT/Microbiology <u>Advances of Basic and Clinical Research of Microbiome in IBD</u>	Oral Session 6
11:00						
12:00						
	Luncheon Seminar 1 Pfizer Japan Inc.	Luncheon Seminar 2 Janssen Pharmaceutical K.K. / Mitsubishi Tanabe Pharma Corporation	Luncheon Seminar 3 Gilead Sciences K.K. / Pharma Co., Ltd. EA	Luncheon Seminar 4 AbbVie GK Medical Affairs	Luncheon Seminar 5 Janssen Asia Pacific	Luncheon Seminar 6 MIYARISAN PHARMACEUTICAL CO., LTD.
13:00						
	Symposium 1 Mucosal Immunology <u>Emerging concepts in pathophysiology of IBD</u>	Session 3 <u>Advances in surgical management of IBD</u>	Oral Session 3	Distinguished 6 <u>Recent advances in host-microbial interaction in IBD</u>	Session 9 <u>Advances in Regenerative Medicine</u>	Oral Session 7
14:00						
	Session 4 IBD-associated cancer <u>Diagnosis and management</u>	Session 5 Pediatric IBD1 Monogenic disease <u>Diagnostic and Therapeutic Challenges in Monogenic IBD</u>	Oral Session 4	Symposium 2 <u>New Advanced Therapies in Asia</u>	Symposium 3 Monitoring (T2T) <u>Monitoring and treat-to-target approach for inflammatory bowel disease</u>	Oral Session 8
15:00						
	Distinguished 3 <u>Biologics and cytokine networks in IBD</u>	Workshop1 COVID-19 <u>Management of IBD under COVID-19 pandemic (or post-corona, before/after)</u>	Oral Session 5	Symposium 4 AOCC-ECCO Forum <u>How to revitalise AOCC projects</u>	Symposium 5 <u>Translational Research in IBD Pathogenesis</u>	Oral Session 9
16:00						
	Evening Seminar 1 Takeda Pharmaceutical Company Limited		Evening Seminar 2 JIMRO Co., Ltd.	Closing Ceremony		
17:00						
18:00						
19:00						